A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease

NCT02307513 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

207

Enrollment

INDUSTRY

Sponsor class

Conditions

Behçet's Syndrome

Interventions

DRUG: Apremilast
DRUG: Placebo

Sponsor

Amgen